Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.
January 2023 AbbVie Inc. Company Confidential
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.